Sugi Predict

Sugi Predict / Targets / IGLV6-57

IGLV6-57

Immunoglobulin lambda variable 6-57 · P01721 · IGLV6-57 on Sugi Atlas →

3,563 patent compounds predicted against IGLV6-57, 2,080 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3763725 SCHEMBL3763725 0.58 10/20
SCHEMBL3834472 SCHEMBL3834472 0.67 9/20
SCHEMBL4922302 SCHEMBL4922302 0.45 9/20
SCHEMBL4696349 SCHEMBL4696349 0.56 8/20
Isoleucine Isoleucine (SCHEMBL4186315) 0.49 7/20
Isoleucine Isoleucine (SCHEMBL7218421) 0.49 7/20
SCHEMBL3632563 SCHEMBL3632563 0.44 7/20
SCHEMBL362294 SCHEMBL362294 0.36 7/20
SCHEMBL67108 SCHEMBL67108 1.00 6/20
SCHEMBL384286 SCHEMBL384286 1.00 6/20
Isothiocyanate Isothiocyanate (SCHEMBL9341143) 0.84 6/20
SCHEMBL3626007 SCHEMBL3626007 0.80 6/20
Coumarin Coumarin (SCHEMBL7593842) 0.76 6/20
SCHEMBL6688557 SCHEMBL6688557 0.76 6/20
SCHEMBL6690441 SCHEMBL6690441 0.73 6/20
SCHEMBL67970 SCHEMBL67970 0.72 6/20
SCHEMBL5964558 SCHEMBL5964558 0.72 6/20
SCHEMBL1942067 SCHEMBL1942067 0.71 6/20
SCHEMBL5964617 SCHEMBL5964617 0.71 6/20
SCHEMBL1752667 SCHEMBL1752667 0.70 6/20

Clinical trials — most relevant to IGLV6-57 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects PHASE4COMPLETED
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases PHASE3COMPLETED
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD PHASE3COMPLETED
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency PHASE3COMPLETED
Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG PHASE3UNKNOWN
Study of PlasmaCap IG in Adults and Children With PIDD PHASE3ACTIVE_NOT_RECRUITING
Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. PHASE3COMPLETED
Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD) PHASE3COMPLETED
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL PHASE2COMPLETED
Elranatamab in R/R Multiple Myeloma PHASE2RECRUITING
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma PHASE2COMPLETED
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas PHASE2COMPLETED
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia PHASE2COMPLETED
Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma PHASE2ACTIVE_NOT_RECRUITING
An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L PHASE2RECRUITING
Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma PHASE2WITHDRAWN
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity PHASE2RECRUITING
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) PHASE2WITHDRAWN
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma PHASE2RECRUITING
ELISA in Relapsed/Refractory MM PHASE2RECRUITING
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma PHASE1COMPLETED
A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma PHASE1COMPLETED
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study PHASE1RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma PHASE1COMPLETED
IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma EARLY_PHASE1NOT_YET_RECRUITING
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma EARLY_PHASE1ACTIVE_NOT_RECRUITING
Heavy Light Chain in Chronic Lymphocytic Leukemia nanUNKNOWN
Oxford Pre-cancerous Lymphoproliferative Disorders Study nanACTIVE_NOT_RECRUITING
MRD Detection by NGS in Pediatric B-ALL nanCOMPLETED
RWE-based Treatment Patterns and Outcomes in CIDP nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a IGLV6-57 binder may also engage these)

ProteinNameSimilarity
P01715 — 0.993 P01715 →
P01704 — 0.992 P01704 →
P01703 — 0.991 P01703 →
A0A0B4J1U3 — 0.991 A0A0B4J1U3 →
P01709 — 0.991 P01709 →
A0A075B6J9 — 0.990 A0A075B6J9 →
P01701 — 0.990 P01701 →
P01717 — 0.989 P01717 →
A0A075B6I6 — 0.989 A0A075B6I6 →
A0A075B6I1 — 0.987 A0A075B6I1 →
A0A075B6K4 — 0.987 A0A075B6K4 →
A0A075B6K0 — 0.986 A0A075B6K0 →
P01706 — 0.986 P01706 →
P01699 — 0.986 P01699 →
P01601 — 0.986 P01601 →
A0A075B6I0 — 0.985 A0A075B6I0 →
P01714 — 0.985 P01714 →
P01705 — 0.985 P01705 →
P80748 — 0.984 P80748 →
P06312 — 0.984 P06312 →
A0A0C4DH25 — 0.983 A0A0C4DH25 →
A0A0C4DH24 — 0.983 A0A0C4DH24 →
A0A075B6H9 — 0.982 A0A075B6H9 →
A0A075B6J1 — 0.982 A0A075B6J1 →
A0A075B6J6 — 0.982 A0A075B6J6 →
P01594 — 0.982 P01594 →
A0A075B6K5 — 0.982 A0A075B6K5 →
A0A087WSX0 — 0.982 A0A087WSX0 →
A0A0A0MT36 — 0.982 A0A0A0MT36 →
A0A0B4J1Y8 — 0.981 A0A0B4J1Y8 →